Synthon and SAJA sign agreement to commercialize a basket of products

Synthon is pleased to announce that it has entered into a partnership with Saudi-based SAJA, to commercialize several products in the MENA region.

SAJA is a joint venture between the premier Saudi healthcare company Tamer Industries and two of the leading Japanese pharmaceutical companies which are Daiichi Sankyo Company Ltd and Astellas Pharma Inc.

Anish Mehta, Chief Executive Officer of Synthon: “We are proud to be partnering with SAJA. We believe this partnership, which brings together the winning combination of Synthon’s high-quality products with SAJA’s local industry-leading expertise, will help accelerate access to high-quality and affordable medicines in the MENA region.”

Mohamed Khalil, Chief Executive Officer of SAJA pharmaceuticals: “Those agreements are  matching with the strategic directions of SAJA pharmaceutical partnerships’ with global pharmaceutical partners,  acquiring the needed experience and technology transfer for moving steadily in the localization of pharmaceutical products in alignment with the economic and pharmaceutical vision 2030 of the kingdom of Saudi Arabia.”

“This unique partnership advances our strategy of further strengthening our commercial presence across the globe by increasing our presence in the MENA region,” says John McCullough, Chief Commercial Officer of Synthon.

About Synthon

Synthon is a global leader in complex generic pharmaceuticals. Our mission is to drive access to medicines and to improve the lives of patients worldwide.